Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2b
Nicole C.C. Them(Austrian Academy of Sciences), Róbert Královics(Medical University of Vienna), Ella Willenbacher(Innsbruck Medical University), Alexander Egle(Paracelsus Medical University), Richard Greil(Paracelsus Medical University), Ernst Schloegl(Hanusch Hospital), Oleh Zagrijtschuk(AOP Orphan (Austria)), Heinz Gisslinger(Medical University of Vienna), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Martin Schalling(Karolinska University Hospital), Christoph Klade(Intercell (Austria)), Doris Chen(University of Kansas), Bettina Gisslinger(Medical University of Vienna), Thomas Melchardt(Paracelsus Medical University), Karin Strecker(Donauspital), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Tiina Berg(Austrian Academy of Sciences), Klaudia Bagienski(Austrian Academy of Sciences), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Guenther Gastl(Innsbruck Medical University), Dominik Wolf(Universität Innsbruck)
Cited by 54
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Bim is a suppressor of Myc-induced mouse B cell leukemia
|Proceedings of the National Academy of Sciences|2004|482
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450